Research ArticleFibrosis

Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis

See allHide authors and affiliations

Science Translational Medicine  30 Sep 2020:
Vol. 12, Issue 563, eaaz5506
DOI: 10.1126/scitranslmed.aaz5506

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Fighting fibrosis through FGF signaling

Excess extracellular matrix deposition by myofibroblasts contributes to fibrosis. Chakraborty et al. studied fibroblast growth factor (FGF) signaling in systemic sclerosis, an idiopathic fibrotic disease. They found that FGF9 signaled through FGF receptor 3 to drive fibroblast-to-myofibroblast transition. Genetic or pharmacological inactivation of this signaling pathway in mouse models of fibrosis and human fibroblasts prevented disease progression and reduced myofibroblast activation. This study identifies FGF receptor 3 signaling as a potential therapeutic target for systemic sclerosis.

View Full Text

Stay Connected to Science Translational Medicine